SCHEMBL3005451

SCHEMBL3005451

Cc1ccc(F)cc1S(=O)(=O)C1CCN(c2nc(Cc3cccc(Br)c3)cs2)CC1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 5/20 0.35
KMT2A Q03164 3/20 0.35
CTSS P25774 1/20 0.35
DCTPP1 Q9H773 1/20 0.34
DNM1L O00429 2/20 0.33
MAPK1 P28482 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 3/20 0.33
MEN1 O00255 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
USP2 O75604 1/20 0.33
RECQL P46063 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014247 0.92 NAAA (0.36) NAAAKMT2ACTSSDCTPP1DNM1L
SCHEMBL3016809 0.91 NAAA (0.40) NAAAKMT2ACTSSDCTPP1DNM1L
SCHEMBL3016948 0.90 CTSS (0.37) NAAAKMT2ACTSSMAPTMEN1
SCHEMBL3018837 0.89 NAAA (0.35) NAAAKMT2ACTSSDNM1LMAPK1
SCHEMBL3007854 0.89 MAPT (0.43) KMT2AMAPK1TP53MAPTMEN1
SCHEMBL3015041 0.88 NAAA (0.36) NAAAKMT2ACTSSDNM1LMAPK1
SCHEMBL3012276 0.88 CTSS (0.47) NAAAKMT2ACTSSMAPTMEN1
SCHEMBL3009006 0.88 SMN1; SMN2 (0.37) NAAACTSSDNM1LMAPK1SMN1; SMN2
SCHEMBL3011191 0.88 NAAA (0.36) NAAAKMT2ADNM1LMAPK1MAPT
SCHEMBL3003779 0.88 NAAA (0.35) NAAAKMT2ACTSSDNM1LMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA NAAA 3229/4885KMT2A 2680/4885CTSS 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.